Skip to main content
Top
Published in: Breast Cancer Research 1/2022

Open Access 01-12-2022 | Breast Cancer | Correction

Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes, Sherene Loi

Published in: Breast Cancer Research | Issue 1/2022

Login to get access

Excerpt

Following publication of the original article [1], the authors identified some errors in Fig. 4. The correct figure is given below.
Metadata
Title
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Authors
Courtney T. van Geelen
Peter Savas
Zhi Ling Teo
Stephen J. Luen
Chen-Fang Weng
Yi-An Ko
Keilly S. Kuykhoven
Franco Caramia
Roberto Salgado
Prudence A. Francis
Sarah-Jane Dawson
Stephen B. Fox
Andrew Fellowes
Sherene Loi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2022
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-022-01539-7

Other articles of this Issue 1/2022

Breast Cancer Research 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine